Mechanism of action of ferroptosis in cholangiocarcinoma

Mingyu YANG; Zhen YANG; Wanhua REN

doi:10.3969/j.issn.1001-5256.2022.04.043

Volume 38 Issue 4

Apr. 2022

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(4): 951-955

PDF( 2261 KB)

Mechanism of action of ferroptosis in cholangiocarcinoma

DOI: 10.3969/j.issn.1001-5256.2022.04.043

Department of Infectious Diseases, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250000, China

Research funding:

National Natural Science Foundation of China (81972606);

Shandong Provincial Natural Science Foundation of China (ZR2019MH005)

More Information

Corresponding author: YANG Zhen, uclnn@hotmail.com(ORCID: 0000-0003-2199-7789)
Received Date: 2021-08-11
Accepted Date: 2021-09-22
Published Date: 2022-04-20

Abstract

Abstract

The incidence and mortality rates of cholangiocarcinoma (CCA) are increasing constantly, and it is of great importance to explore new therapeutic targets. Ferroptosis, a unique pattern of cell death caused by iron-dependent cellular oxidative injury, is closely associated with iron metabolism and oxidative stress imbalance in cancer and has become a research hotspot in the field of tumor. This article introduces the mechanism of ferroptosis and the research advances in ferroptosis involved in the development and progression of CCA, and it is pointed out that the regulatory mechanism of ferroptosis has an important clinical value in the malignant progression of CCA.
- Bile Duct Neoplasms,
- Ferroptosis,
- Pathologic Processes

FullText(HTML)

References(45)

References

[1]	DIXON SJ, LEMBERG KM, LAMPRECHT MR, et al. Ferroptosis: An iron-dependent form of nonapoptotic cell death[J]. Cell, 2012, 149(5): 1060-1072. DOI: 10.1016/j.cell.2012.03.042.
[2]	YAMADA N, KARASAWA T, KIMURA H, et al. Ferroptosis driven by radical oxidation of n-6 polyunsaturated fatty acids mediates acetaminophen-induced acute liver failure[J]. Cell Death Dis, 2020, 11(2): 144. DOI: 10.1038/s41419-020-2334-2.
[3]	LI J, CAO F, YIN HL, et al. Ferroptosis: Past, present and future[J]. Cell Death Dis, 2020, 11(2): 88. DOI: 10.1038/s41419-020-2298-2.
[4]	XU X, LAI Y, HUA ZC. Apoptosis and apoptotic body: Disease message and therapeutic target potentials[J]. Biosci Rep, 2019, 39(1): BSR20180992. DOI: 10.1042/BSR20180992.
[5]	GALLUZZI L, GREEN DR. Autophagy-independent functions of the autophagy machinery[J]. Cell, 2019, 177(7): 1682-1699. DOI: 10.1016/j.cell.2019.05.026.
[6]	LEE H, ZANDKARIMI F, ZHANG Y, et al. Energy-stress-mediated AMPK activation inhibits ferroptosis[J]. Nat Cell Biol, 2020, 22(2): 225-234. DOI: 10.1038/s41556-020-0461-8.
[7]	CHEN X, KANG R, KROEMER G, et al. Broadening horizons: The role of ferroptosis in cancer[J]. Nat Rev Clin Oncol, 2021, 18(5): 280-296. DOI: 10.1038/s41571-020-00462-0.
[8]	ZHANG FY, ADILA·YKP, ZHAO JM, et al. Mechanism of ferroptosis and its role in liver diseases[J]. J Clin Hepatol, 2021, 37(6): 1454-1458. DOI: 10.3969/j.issn.1001-5256.2021.06.049. 张飞宇, 阿迪拉·亚克普, 赵金明, 等. 铁死亡的发生机制及在肝脏疾病中的作用[J]. 临床肝胆病杂志, 2021, 37(6): 1454-1458. DOI: 10.3969/j.issn.1001-5256.2021.06.049.
[9]	DIXON SJ, WINTER GE, MUSAVI LS, et al. Human haploid cell genetics reveals roles for lipid metabolism genes in nonapoptotic cell death[J]. ACS Chem Biol, 2015, 10(7): 1604-1609. DOI: 10.1021/acschembio.5b00245.
[10]	FEI W, CHEN D, TANG H, et al. Targeted GSH-exhausting and hydroxyl radical self-producing manganese-silica nanomissiles for MRI guided ferroptotic cancer therapy[J]. Nanoscale, 2020, 12(32): 16738-16754. DOI: 10.1039/d0nr02396e.
[11]	BANNING A, BRIGELIUS-FLOHÉ R. NF-kappaB, Nrf2, and HO-1 interplay in redox-regulated VCAM-1 expression[J]. Antioxid Redox Signal, 2005, 7(7-8): 889-899. DOI: 10.1089/ars.2005.7.889.
[12]	YANG WS, SRIRAMARATNAM R, WELSCH ME, et al. Regulation of ferroptotic cancer cell death by GPX4[J]. Cell, 2014, 156(1-2): 317-331. DOI: 10.1016/j.cell.2013.12.010.
[13]	JIANG L, KON N, LI T, et al. Ferroptosis as a p53-mediated activity during tumour suppression[J]. Nature, 2015, 520(7545): 57-62. DOI: 10.1038/nature14344.
[14]	SATO M, KUSUMI R, HAMASHIMA S, et al. The ferroptosis inducer erastin irreversibly inhibits system xc- and synergizes with cisplatin to increase cisplatin's cytotoxicity in cancer cells[J]. Sci Rep, 2018, 8(1): 968. DOI: 10.1038/s41598-018-19213-4.
[15]	CHEN D, TAVANA O, CHU B, et al. NRF2 is a major target of ARF in p53-independent tumor suppression[J]. Mol Cell, 2017, 68(1): 224-232. e4. DOI: 10.1016/j.molcel.2017.09.009.
[16]	SHIMADA K, SKOUTA R, KAPLAN A, et al. Global survey of cell death mechanisms reveals metabolic regulation of ferroptosis[J]. Nat Chem Biol, 2016, 12(7): 497-503. DOI: 10.1038/nchembio.2079.
[17]	SILVA I, RAUSCH V, PECCERELLA T, et al. Hypoxia enhances H2O2-mediated upregulation of hepcidin: Evidence for NOX4-mediated iron regulation[J]. Redox Biol, 2018, 16: 1-10. DOI: 10.1016/j.redox.2018.02.005.
[18]	JIA F, SONG N, WANG W, et al. High dietary iron supplement induces the nigrostriatal dopaminergic neurons lesion in transgenic mice expressing mutant A53T human alpha-synuclein[J]. Front Aging Neurosci, 2018, 10: 97. DOI: 10.3389/fnagi.2018.00097.
[19]	SUN X, OU Z, XIE M, et al. HSPB1 as a novel regulator of ferroptotic cancer cell death[J]. Oncogene, 2015, 34(45): 5617-5625. DOI: 10.1038/onc.2015.32.
[20]	SUN X, OU Z, CHEN R, et al. Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells[J]. Hepatology, 2016, 63(1): 173-184. DOI: 10.1002/hep.28251.
[21]	YANG M, LI X, LI H, et al. Baicalein inhibits RLS3-induced ferroptosis in melanocytes[J]. Biochem Biophys Res Commun, 2021, 561: 65-72. DOI: 10.1016/j.bbrc.2021.05.010.
[22]	ASSAILY W, RUBINGER DA, WHEATON K, et al. ROS-mediated p53 induction of Lpin1 regulates fatty acid oxidation in response to nutritional stress[J]. Mol Cell, 2011, 44(3): 491-501. DOI: 10.1016/j.molcel.2011.08.038.
[23]	ZHANG Y, FENG X, ZHANG J, et al. Iron regulatory protein 2 is a suppressor of mutant p53 in tumorigenesis[J]. Oncogene, 2019, 38(35): 6256-6269. DOI: 10.1038/s41388-019-0876-5.
[24]	CHANG HW, LEE M, LEE YS, et al. p53-dependent glutamine usage determines susceptibility to oxidative stress in radioresistant head and neck cancer cells[J]. Cell Signal, 2021, 77: 109820. DOI: 10.1016/j.cellsig.2020.109820.
[25]	TSAI TF, CHEN PC, LIN YC, et al. Miconazole contributes to NRF2 activation by noncanonical P62-KEAP1 pathway in bladder cancer cells[J]. Drug Des Devel Ther, 2020, 14: 1209-1218. DOI: 10.2147/DDDT.S227892.
[26]	SUN Y, HE L, WANG T, et al. Activation of p62-Keap1-Nrf2 pathway protects 6-hydroxydopamine-induced ferroptosis in dopaminergic cells[J]. Mol Neurobiol, 2020, 57(11): 4628-4641. DOI: 10.1007/s12035-020-02049-3.
[27]	DOLL S, FREITAS FP, SHAH R, et al. FSP1 is a glutathione-independent ferroptosis suppressor[J]. Nature, 2019, 575(7784): 693-698. DOI: 10.1038/s41586-019-1707-0.
[28]	BERSUKER K, HENDRICKS JM, LI Z, et al. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis[J]. Nature, 2019, 575(7784): 688-692. DOI: 10.1038/s41586-019-1705-2.
[29]	GAO M, YI J, ZHU J, et al. Role of mitochondria in ferroptosis[J]. Mol Cell, 2019, 73(2): 354-363. e3. DOI: 10.1016/j.molcel.2018.10.042.
[30]	BANALES JM, CARDINALE V, CARPINO G, et al. Expert consensus document: Cholangiocarcinoma: Current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)[J]. Nat Rev Gastroenterol Hepatol, 2016, 13(5): 261-280. DOI: 10.1038/nrgastro.2016.51.
[31]	WEIGT J, MALFERTHEINER P. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer[J]. Expert Rev Gastroenterol Hepatol, 2010, 4(4): 395-397. DOI: 10.1586/egh.10.45.
[32]	HAN JY, AHN KS, BAEK WK, et al. Usefulness of bile as a biomarker via ferroptosis and cysteine prenylation in cholangiocarcinoma; role of diagnosis and differentiation from benign biliary disease[J]. Surg Oncol, 2020, 34: 174-181. DOI: 10.1016/j.suronc.2020.04.019.
[33]	MOHR R, ÖZDIRIK B, KNORR J, et al. In vivo models for cholangiocarcinoma-what can we learn for human disease?[J]. Int J Mol Sci, 2020, 21(14): 4993. DOI: 10.3390/ijms21144993.
[34]	PARK JH, PYUN WY, PARK HW. Cancer metabolism: Phenotype, signaling and therapeutic targets[J]. Cells, 2020, 9(10): 2038. DOI: 10.3390/cells9102308.
[35]	KIRTONIA A, SETHI G, GARG M. The multifaceted role of reactive oxygen species in tumorigenesis[J]. Cell Mol Life Sci, 2020, 77(22): 4459-4483. DOI: 10.1007/s00018-020-03536-5.
[36]	GANZ T. Systemic iron homeostasis[J]. Physiol Rev, 2013, 93(4): 1721-1741. DOI: 10.1152/physrev.00008.2013.
[37]	MANCINELLI R, CUTONE A, ROSA L, et al. Different iron-handling in inflamed small and large cholangiocytes and in small and large-duct type intrahepatic cholangiocarcinoma[J]. Eur J Histochem, 2020, 64(4): 3156. DOI: 10.4081/ejh.2020.3156.
[38]	THANAN R, OIKAWA S, YONGVANIT P, et al. Inflammation-induced protein carbonylation contributes to poor prognosis for cholangiocarcinoma[J]. Free Radic Biol Med, 2012, 52(8): 1465-1472. DOI: 10.1016/j.freeradbiomed.2012.01.018.
[39]	JAMNONGKAN W, THANAN R, TECHASEN A, et al. Upregulation of transferrin receptor-1 induces cholangiocarcinoma progression via induction of labile iron pool[J]. Tumour Biol, 2017, 39(7): 1010428317717655. DOI: 10.1177/1010428317717655.
[40]	TRAN KT, COLEMAN HG, MCCAIN RS, et al. Serum biomarkers of iron status and risk of primary liver cancer: A systematic review and meta-analysis[J]. Nutr Cancer, 2019, 71(8): 1365-1373. DOI: 10.1080/01635581.2019.1609053.
[41]	CHEN GQ, BENTHANI FA, WU J, et al. Artemisinin compounds sensitize cancer cells to ferroptosis by regulating iron homeostasis[J]. Cell Death Differ, 2020, 27(1): 242-254. DOI: 10.1038/s41418-019-0352-3.
[42]	MA B, MENG H, TIAN Y, et al. Distinct clinical and prognostic implication of IDH1/2 mutation and other most frequent mutations in large duct and small duct subtypes of intrahepatic cholangiocarcinoma[J]. BMC Cancer, 2020, 20(1): 318. DOI: 10.1186/s12885-020-06804-6.
[43]	NABESHIMA T, HAMADA S, TAGUCHI K, et al. Keap1 deletion accelerates mutant K-ras/p53-driven cholangiocarcinoma[J]. Am J Physiol Gastrointest Liver Physiol, 2020, 318(3): g419-g427. DOI: 10.1152/ajpgi.00296.2019.
[44]	YE Z, HU Q, ZHUO Q, et al. Abrogation of ARF6 promotes RSL3-induced ferroptosis and mitigates gemcitabine resistance in pancreatic cancer cells[J]. Am J Cancer Res, 2020, 10(4): 1182-1193.
[45]	LEE J, YOU JH, SHIN D, et al. Inhibition of glutaredoxin 5 predisposes cisplatin-resistant head and neck cancer cells to ferroptosis[J]. Theranostics, 2020, 10(17): 7775-7786. DOI: 10.7150/thno.46903.

Relative Articles

[1]	Minyue LI, Hongju YANG, Jing LI, Rui SONG, Jing YOU. Association of signal transducer and activator of transcription 3 and signal transducer and activator of transcription 5 with regulatory T cell/T helper 17 cell balance in chronic hepatitis B[J]. Journal of Clinical Hepatology, 2022, 38(6): 1393-1397. doi: 10.3969/j.issn.1001-5256.2022.06.036
[2]	Guangjun TANG, Jing YOU, Huai'e LIU, Yujuan PENG. Role of T helper 17 cell/regulatory T cell imbalance in the progression of HBV-related liver diseases[J]. Journal of Clinical Hepatology, 2021, 37(2): 414-418. doi: 10.3969/j.issn.1001-5256.2021.02.035
[3]	Xue Miao, Mao XiaoRong, Chen Hong. Change in T helper 17 cell/regulatory T cell imbalance in rats with immunological liver injury[J]. Journal of Clinical Hepatology, 2020, 36(1): 149-152. doi: 10.3969/j.issn.1001-5256.2020.01.033
[4]	YANG JingShu, LI Ning. Research advances in T helper 17 cells in chronic inflammatory liver diseases[J]. Journal of Clinical Hepatology, 2020, 36(12): 2808-2810. doi: 10.3969/j.issn.1001-5256.2020.12.034
[5]	Wang WeiZhao, Xiang XiaoXing. Immunological mechanism of Treg/Th17 and Th1/Th2 balance in autoimmune hepatitis and new targets for diagnosis and treatment[J]. Journal of Clinical Hepatology, 2019, 35(8): 1874-1877. doi: 10.3969/j.issn.1001-5256.2019.08.051
[6]	Deng WeiWei, Zhu WenMing, Yi Chao, Feng YangChun, Huang YanChun. Association of serum interleukin-17 level with early recurrence and prognosis after radical surgery in hepatocellular carcinoma patients with different levels of alpha-fetoprotein[J]. Journal of Clinical Hepatology, 2018, 34(2): 298-302. doi: 10.3969/j.issn.1001-5256.2018.02.016
[7]	Yang JingYi, Cheng ShuQuan, Cao YaZhao, Huang ChengJun, Jiang FuMing. Expression of Toll-like receptors 2 and 3 in liver tissue and its clinical significance in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2018, 34(2): 276-280. doi: 10.3969/j.issn.1001-5256.2018.02.012
[8]	Yang PuJuan, Huang Yi, Liu HuaBao. Research advances in the association between interleukin-17 and liver diseases[J]. Journal of Clinical Hepatology, 2017, 33(9): 1810-1814. doi: 10.3969/j.issn.1001-5256.2017.09.041
[9]	Li KeXin, Zang MengYa, Wang DongMei, He Huan, Wang YuTing, Qu ChunFeng. Effect of interleukin-17A on stemness of hepatoma cell lines[J]. Journal of Clinical Hepatology, 2017, 33(6): 1131-1136. doi: 10.3969/j.issn.1001-5256.2017.06.023
[10]	Li XiaoTian, Yin Yan, Guo YongZe, Zhou LiYun, You ZiXuan. Mechanism of action of 1,25(OH)_2D_3 in influencing the expression of interleukin-17 and macrophage inflammatory protein-3α and inhibiting the formation of liver fibrosis in rats[J]. Journal of Clinical Hepatology, 2016, 32(12): 2331-2336. doi: 10.3969/j.issn.1001-5256.2016.12.020
[11]	Hao TingTing, Ma XiaoPeng, Wen YanLi, Dai GuangRong, Feng YiChao, Zhang Li. Changes in serum levels of M30,M65,and IL-17 and their clinical significance in patients with acute pancreatitis[J]. Journal of Clinical Hepatology, 2016, 32(2): 329-332. doi: 10.3969/j.issn.1001-5256.2016.02.027
[12]	Cao ZhenHuan, Liu YaLi, Ma LiNa, Lu JunFeng, Jin Yi, He ZhiMin, Zheng YanHong, Chen XinYue. Association between serum level of interleukin-17 and HBsAg clearance in patients with HBsAg-negative chronic hepatitis B[J]. Journal of Clinical Hepatology, 2016, 32(7): 1292-1295. doi: 10.3969/j.issn.1001-5256.2016.07.015
[13]	Li CaiDong, Yang YongWei, Li HuiJun, Tian PengFei, Wu Bin. Changes in peripheral plasma concentrations of macrophage migration inhibitory factor,interleukin-17,and interleukin-10 and their correlations with HBV DNA load in chronic HBV carriers[J]. Journal of Clinical Hepatology, 2015, 31(5): 702-705. doi: 10.3969/j.issn.1001-5256.2015.05.017
[14]	Wu Qin, Meng FanPing, Ma XueMei, Jin Bo, Shen LiJun, Wu LiBing, Chu JinDong, Lai WenHui, Han JingJing, Li HanWei. Analysis of association between different HCV genotypes and serum interleukin-17, interleukin-6, and vitamin D in patients with HCV-related cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(11): 1849-1852. doi: 10.3969/j.issn.1001-5256.2015.11.019
[15]	Liu ChaoHui, Chen YiJie, Zhang ChengHua. Effects of splenectomy on peripheral blood Th17 cells and immune function in patients with portal hypertension[J]. Journal of Clinical Hepatology, 2014, 30(9): 887-890. doi: 10.3969/j.issn.1001-5256.2014.09.012
[16]	Wei LinLin, Zhou Li, Shi HongBo, Duan ZhongPing. Role of Th17 cells in common liver diseases[J]. Journal of Clinical Hepatology, 2013, 29(6): 477-480.
[17]	Guan HaiTao, Zhao JinLi, Tang Rui, Sun LinLin. IL-17 promotes expression of fibrosis-related factors in hepatic stellate cells[J]. Journal of Clinical Hepatology, 2013, 29(5): 370-374.
[18]	Hong YuBo, Zhang Ting, Sun LiGuang. Association between IL-2 +114 (G/T) polymorphism and susceptibility to hepatitis B, cirrhosis, and hepatocellular carcinoma in Jilin province[J]. Journal of Clinical Hepatology, 2012, 28(12): 930-933.
[19]	Qin JianJie, Lu: Ling. The role and molecular mechanism of interleukin-17 in organ transplant rejection[J]. Journal of Clinical Hepatology, 2012, 28(11): 812-814.
[20]	Yang Bo, Zhao CaiYan. Advanced research on Th17 cell and its relevant role in the progress liver diseases[J]. Journal of Clinical Hepatology, 2011, 27(2): 206-209.

Supplements(0)

Cited By

Cited by

Periodical cited type(3)

1.	周晓菊，邓威，杨丽. 医学检验科检查肝硬化疾病的临床应用价值. 黑龙江医学. 2024(11): 1340-1342 .
2.	张琳，冯晓彬，黄鑫，梁子威，何作祥，卢倩，董家鸿. 钇-90微球选择性内放射治疗在肝癌降期转化移植中的应用进展. 中华消化外科杂志. 2024(12): 1566-1570 .
3.	余敏，李歆. 528例卡瑞利珠单抗治疗的免疫相关不良反应及风险因素分析. 中国药物警戒. 2023(10): 1134-1140 .

Other cited types(2)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(1)

Get Citation

PDF

XML

Article Metrics

Article views (1334) PDF downloads(132)

Mechanism of action of ferroptosis in cholangiocarcinoma

DOI: 10.3969/j.issn.1001-5256.2022.04.043